The IQVIA Core Diabetes Model (CDM)
The IQVIA Core Diabetes Model (CDM) is a web accessible model that simulates disease progression in both type 1 and type 2 diabetes.
The IQVIA is a micro-simulation model designed to translate surrogate endpoints to long term health economic outcomes.
The model is mainly informed from landmark studies and peer reviewed publications, with continuous updates. The last available version is version 10, released in May 2024.
Adaptation and calibration to specific geographies or clinical trials results is possible.
|
The IQVIA Core Diabetes Model (CDM) as a tool for policy analysis and reimbursement strategies in diabetes
The model is a versatile tool with several pharmaco-economics and public health applications:
- Treatment Comparisons: Researchers and clinicians can use the CDM to compare different treatment strategies, assessing their effectiveness in managing diabetes.
- Cost-Effectiveness Analysis: The CDM may estimates long-term costs and benefits associated to new technologies (both drugs and medical devices) in diabetes.
- Budget Impact Analysis: Organizations may assess the financial impact of implementing specific diabetes interventions using the CDM.
- Guidelines Drafting: The CDM may inform the development of evidence-based clinical guidelines for diabetes management.
- Policy Decision Support: Healthcare policymakers leverage the CDM for resource allocation and preventive measures.
- Patient Education: The CDM may be used to educate patients about the long-term consequences of diabetes.
|
